Interim 75 patients Data might be good (Dec 14th Week)Based on the evidence generated by 2 independent groups speaks in favor of the positive outcomes -
1) https://msystems.asm.org/content/msys/4/6/e00431-19.full.pdf -
This was pub in 2019 Dec just when COVID was being detected for the first time. The Chinese group clearly showed a positive impact of Ifenprodil on H5N1-induced-Acute lung injury mouse model through alleviation of H5N1-induced cytokine storm in mouse lungs (Fig 3, Ifenprodil dubbed No.42)
2) https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7263237&blobtype=pdf
This was pub in 2020 May by University of Texas group. These findings reveal a potential new pathway for sensory modulation of lung pathophysiology involving glutamate from sensory afferents acting on NMDA receptors expressed by resident cells in the lung.
This data will break or make Algernon. I would have been more excited to see Ifenprodil patient activity in Cough/IPF rather in COVID indication, but this will be the first time AGN would showcase Ifenprodil relevance. Any positive outcome might shoot up this company to $1 zone. And this will help AGN to raise $10-15M for successfuly running/finishing Ifenprodil relevancy in Cough/IPF.
Fingers Crossed !